title: Phase II trial of 5-fluorouracil and high-dose folinic acid in advanced renal cell cancer.
abstract: Fourteen patients with metastatic renal cell carcinoma (RCC) were treated with high-dose folinic acid (HDFA): 200 mg/m2 i.v. and 5-fluorouracil (5-FU): 370 mg/m2 i.v. for 5 consecutive days every 28 days. Severe oral mucositis (WHO grade III-IV) was experienced by two patients, whereas hematological toxicity was mild. No complete or partial remission was observed. Short-lasting stable disease occurred in 8 patients (median = 5 months, range 2-11). This combination does not need further evaluation in patients with RCC.
authors.affiliation: Servizio di Oncologia, Spedali Civili, Brescia, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Zaniboni
authors.forename: E
authors.initials: E
authors.lastname: Simoncini
authors.forename: P
authors.initials: P
authors.lastname: Marpicati
authors.forename: E
authors.initials: E
authors.lastname: Montini
authors.forename: V
authors.initials: V
authors.lastname: Ferrari
authors.forename: G
authors.initials: G
authors.lastname: Marini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000556:secondary; D004341:Drug Evaluation; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy*; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged
chemical_list: D002955:Leucovorin; D005472:Fluorouracil